(Q46542092)

English

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

scientific article published on 22 July 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Silvio Marco Veronese

5

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

Roberto Labianca

15

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

Giuseppe Giaccone

17

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

20

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

9

object named as

Flavia Longo

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

Calogero Lauricella

14

object named as

Calogero Lauricella

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

author name string

Marina Chiara Garassino

1

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

Olga Martelli

2

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

Massimo Broggini

3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

Gabriella Farina

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

Eliana Rulli

6

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

Filippo Bianchi

7

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

Anna Bettini

8

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

Luca Moscetti

10

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

Maurizio Tomirotti

11

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

Mirko Marabese

12

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

Monica Ganzinelli

13

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

Irene Floriani

16

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

Valter Torri

18

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

Alberto Scanni

19

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

TAILOR trialists

21

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

publication date

22 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

14

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

10

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

981-988

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Testing epidermal growth factor receptor mutations in patients with non-small-cell lung cancer to choose chemotherapy: the other side of the coin.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor recep

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized clinical trials with biomarkers: design issues

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Mode of action and application of Scorpion primers to mutation detection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Detecting an overall survival benefit that is derived from progression-free survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

KRAS mutation: should we test for it, and does it matter?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Circumventing cancer drug resistance in the era of personalized medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Cancer. Addiction to oncogenes--the Achilles heal of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

New targetable oncogenes in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970310-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(13)70310-3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

release_5lvtpfp7gbdufgo2ouzlrytoui

1 reference

https://api.fatcat.wiki/v0/release/5lvtpfp7gbdufgo2ouzlrytoui

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23883922

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46542092&oldid=2116983967"